^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MBS314

    i
    Other names: MBS314
    Associations

    News

    Trials
    Company:
    Beijing Mabworks Biotech, KYinno
    Drug class:
    CD3 agonist, BCMA inhibitor, GPRC5D inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MBS314
    2ms
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Not yet recruiting, Beijing Mabworks Biotech Co., Ltd. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date
    |
    MBS314
    4ms
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Not yet recruiting, Beijing Mabworks Biotech Co., Ltd.
    New P1/2 trial
    |
    MBS314
    1year
    A novel T-cell-engaging therapeutical antibody against GPRC5D&BCMA for multiple myeloma treatment (AACR 2023)
    T-cell-engaging therapeutical antibodies, such as Talquetamab (targeting GPRC5D and CD3 with 1:1 formation) and CC-93269(targeting BCMA and CD3 with 2:1 formation) have shown promise in multiple myeloma (MM) treatment. In addition, owning to the low affinity to CD3, MBS314 has no detectable toxicity in CD3 humanized mice. In summary, our data show MBS314 is a promising TCE for MM treatment with high efficacy and broad spectrum targeting both GPRC5D and BCMA, and also has excellent safety with low CD3 binding affinity.
    IO biomarker
    |
    SDC1 (Syndecan 1) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    Talvey (talquetamab-tgvs) • alnuctamab (CC-93269) • MBS314